Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice

Immunological Investigations

Volumn 45, Issue 6, 2016, Pages 553-565

  Jung, Nam Chul ^a   Lee, Jun Ho ^b   Choi, Hyun Ji ^b   Hwang, Sung Uk ^a   Song, Jie Young ^c   Seo, Han Geuk ^d   Choi, Jinjung ^e   Jung, Sang Youn ^e   Han, Sung Gu ^d   Lim, Dae Seog ^b  

^a Pharos Vaccine Inc   (South Korea)

^b CHA University   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

^d Konkuk University   (South Korea)

^e CHA Bundang Medical Center   (South Korea)

Author keywords

Cytokine induced killer cells; dendritic cells; hepatocellular carcinoma

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; LACTATE DEHYDROGENASE; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL LYSATE; CELL THERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RELEASE ASSAY; TUMOR GROWTH; ADOPTIVE TRANSFER; ANIMAL; C3H MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; SECRETION (PROCESS); SURVIVAL ANALYSIS; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C3H; PRIMARY CELL CULTURE; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84978524657     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820139.2016.1183025     Document Type: Article

References (28)

1. M.H.Andersen, P.Keikavoussi, E.B.Brocker, et al. (2001). Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression. Int J Cancer, 94 (6), 820–4.
2. H.Asada, T.Kishida, H.Hirai, et al. (2006). Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Cancer Lett, 240 (1), 83–93. doi: 10.1016/j.canlet.2005.08.030.
3. J.Baker, M.R.Verneris, M.Ito, et al. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood, 97 (10), 2923–31.
4. J.Banchereau, R.M.Steinman (1998). Dendritic cells and the control of immunity. Nature, 392 (6673), 245–52. doi: 10.1038/32588.
5. D.H.Chang, M.V.Dhodapkar (2003). Dendritic cells and immunotherapy for cancer. Int J Hematol, 77 (5), 439–43.
6. X.Z.Duan, H.Zhuang, M.Wang, et al. (2005). Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J Gastroenterol Hepatol, 20 (2), 234–42. doi: 10.1111/j.1440-1746.2004.03529.x.
7. H.B.El-Serag (2011). Hepatocellular carcinoma. N Engl J Med, 365 (12), 1118–27. doi: 10.1056/NEJMra1001683.
8. H.B.El-Serag, K.L.Rudolph (2007). Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterol, 132 (7), 2557–76. doi: 10.1053/j.gastro.2007.04.061.
9. K.Eshima, S.Chiba, H.Suzuki, et al. (2012). Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol Lett, 144 (1–2), 7–15. doi: 10.1016/j.imlet.2012.02.013.
10. I.Ikai, S.Arii, M.Okazaki, et al. (2007). Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res, 37 (9), 676–91. doi: 10.1111/j.1872-034X.2007.00119.x.
11. S.Kakumu, S.Ito, T.Ishikawa, et al. (2000). Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol, 15 (4), 431–6.
12. K.Khazaie, H.von Boehmer (2006). The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol, 16 (2), 124–36. doi: 10.1016/j.semcancer.2005.11.006.
13. Y.Kondo, T.Shimosegawa (2015). Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Int J Mol Sci, 16 (2), 3307–22. doi: 10.3390/ijms16023307.
14. D.S.Lim, J.H.Kim, D.S.Lee, et al. (2007). DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol Immunother, 56 (11), 1817–29. doi: 10.1007/s00262-007-0325-0.
15. P.H.Lu, R.S.Negrin (1994). A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol, 153 (4), 1687–96.
16. I.Mellman, R.M.Steinman (2001). Dendritic cells: Specialized and regulated antigen processing machines. Cell 106 (3), 255–8.
17. F.O.Nestle, S.Alijagic, M.Gilliet, et al. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 4 (3), 328–32.
18. H.Nishikawa, A.Arimoto, T.Wakasa, et al. (2013). Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer, 4 (6), 502–13. doi: 10.7150/jca.6503.
19. D.W.O’Neill, S.Adams, N.Bhardwaj (2004). Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood, 104 (8), 2235–46. doi: 10.1182/blood-2003-12-4392.
20. J.Schmidt, S.Eisold, M.W.Buchler, A.Marten (2004). Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 53 (11), 1018–26. doi: 10.1007/s00262-004-0554-4.
21. I.G.Schmidt-Wolf, P.Lefterova, B.A.Mehta, et al. (1993). Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol, 21 (13), 1673–9.
22. I.G.Schmidt-Wolf, R.S.Negrin, H.P.Kiem, et al. (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med, 174 (1), 139–49.
23. F.Tada, M.Abe, M.Hirooka, et al. (2012). Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol, 41 (5), 1601–9. doi: 10.3892/ijo.2012.1626.
24. M.Vivarelli, R.Montalti, A.Risaliti (2013). Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World J Gastroenterol, 19 (42), 7316–26. doi: 10.3748/wjg.v19.i42.7316.
25. J.S.Yu, G.Liu, H.Ying, et al. (2004). Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res, 64 (14), 4973–9. doi: 10.1158/0008-5472.CAN-03-3505.
26. B.F.Zamarron, W.Chen (2011). Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci, 7 (5), 651–8.
27. H.Q.Zhao, W.M.Li, Z.Q.Lu, Y.M.Yao (2014). Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis. World J Gastroenterol, 20 (24), 7971–8. doi: 10.3748/wjg.v20.i24.7971.
28. R.Zhong, J.Teng, B.Han, H.Zhong (2011). Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother, 60 (10), 1497–502. doi: 10.1007/s00262-011-1060-0.